Additional Studies Demonstrate PuriCore's Sterilox Solution Effective against Major Outbreak Pathogens.

Sterilox Tested against Norovirus, MRSA, Acinetobacter, and Influenza

MALVERN, Pa. & STAFFORD, England -- PuriCore (LSE: PURI), the life sciences company focused on the development and commercialization of its novel, safe antimicrobial technology, will present results of several recent studies showing that its Sterilox Solution effectively decontaminates hard surfaces infected with norovirus, methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter, and human influenza--all considered major outbreak pathogens--at the National Environmental Health Association Conference (NEHA) this week. The Sterilox Solution, which mimics the natural anti-microbial hypochlorous acid produced by the human body to fight pathogens, is used in a broad range of markets that depend upon controlling contamination, including food safety, medical device disinfection, wound management, and hospitality.

One of the studies, conducted by the research team of Dr. Mark Sobsey at the University of North Carolina (UNC), tested the effectiveness of the Sterilox Solution in decontaminating norovirus, the most frequent cause of viral gastroenteritis outbreaks worldwide, in both laboratory tests and a real-world, room-decontamination setting. The study showed that the Sterilox Solution, when administered as a spray or as a fog, was rapidly effective at disinfecting room surfaces contaminated with norovirus. The researchers utilized a norovirus strain obtained from an actual outbreak (rather than a commonly tested surrogate), and the tests were performed successfully on both porous and non-porous surfaces.

"These studies continue to demonstrate that our safe and environmentally friendly Sterilox Solution is highly effective against the spread of these pathogens," said Greg Bosch, CEO of PuriCore. "Our technology has potential for use in a variety of settings from hospitals, schools, and supermarkets to hotels, cruise ships, and other public facilities."

Mark Sampson, PhD, PuriCore's Director of Microbiology, will present results of the UNC norovirus study on Thursday, June 21, at the NEHA Conference in Atlantic City, New Jersey, and at the Aerobiology in Biodefense II Conference, sponsored by the National Institutes of Health and the US Army Medical Research Institute, in July. In addition, results of this study will be published in the next issue of The Journal of Applied and Environmental Microbiology (abstract available).

Dr. Sampson's NEHA presentation will also report results from recent studies published in the Journal of Hospital Infection performed by Dr. Steve Barrett's research team at Charing Cross Hospital in London that demonstrated the antimicrobial activity of the Sterilox Solution fog in decontaminating MRSA and Acinetobacter clinical isolates dried onto surfaces. In addition, he will present findings from studies performed at independent labs that demonstrated the virucidal activity of the Sterilox Solution when sprayed or fogged against the human influenza virus (A/Hong Kong 68 Strain, a common surrogate for the pandemic H5N1 avian influenza strain) dried onto surfaces.

About PuriCore

PuriCore (London Stock Exchange: PURI) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety, medical device disinfection, wound management, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of M. tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our web site at www.puricore.com, which does not form part of this press release.